PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Rene-Olivier Casasnovas 1 Reda Bouabdallah 2 Pauline Brice 3 Julien Lazarovici 4 Hervé Ghesquieres 5 Aspasia Stamatoullas 6 Jehan Dupuis 7 Anne-Claire Gac 8 Thomas Gastinne 9 Bertrand Joly 10 Krimo Bouabdallah 11 Emmanuelle Nicolas-Virelizier 12 Pierre Feugier 13 Franck Morschhauser 14 Richard Delarue 15 Hassan Farhat 16 Philippe Quittet 17 Alina Berriolo-Riedinger 18 Adrian Tempescul 19, 20 Véronique Edeline 21 Hervé Maisonneuve 22 Luc-Matthieu Fornecker 23 Thierry Lamy 24 Alain Delmer 25 Peggy Dartigues 26 Laurent Martin 27 Marc Andre 28 Nicolas Mounier 29 Alexandra Traverse-Glehen 5 Michel Meignan 30
Abstract : Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) improves progression-free survival in patients with advanced Hodgkin lymphoma compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), but is associated with increased risks of haematological toxicity, secondary myelodysplasia or leukaemia, and infertility. We investigated whether PET monitoring during treatment could allow dose de-escalation by switching regimen (BEACOPPescalated to ABVD) in early responders without loss of disease control compared with standard treatment without PET monitoring.
Document type :
Journal articles
Complete list of metadatas

https://hal.univ-brest.fr/hal-02263798
Contributor : Geneviève Michel <>
Submitted on : Monday, August 5, 2019 - 4:51:13 PM
Last modification on : Tuesday, October 15, 2019 - 10:00:04 AM

Identifiers

Citation

Rene-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Hervé Ghesquieres, et al.. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. The Lancet Oncology, 2019, 20 (2), pp.202-215. ⟨10.1016/S1470-2045(18)30784-8⟩. ⟨hal-02263798⟩

Share

Metrics

Record views

45